Bionano Genomics, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported revenue was USD 6.67 million compared to USD 3.86 million a year ago. Net loss was USD 32.16 million compared to USD 18.79 million a year ago. Basic loss per share from continuing operations was USD 0.11 compared to USD 0.07 a year ago. Diluted loss per share from continuing operations was USD 0.11 compared to USD 0.07 a year ago.
For the six months, revenue was USD 12.37 million compared to USD 7.02 million a year ago. Net loss was USD 62.11 million compared to USD 28.73 million a year ago. Basic loss per share from continuing operations was USD 0.22 compared to USD 0.11 a year ago. Diluted loss per share from continuing operations was USD 0.22 compared to USD 0.11 a year ago.